1-4 of 4
Hillary Prescott
Close
Sort by
Journal Articles

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Patrick McBride, PharmD, Houry Leblebjian, PharmD, Paul Richardson, Jacob Laubach, MD, Hillary Prescott, PharmD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3234.
https://doi.org/10.1182/blood-2018-99-111361
Published: 2018
Journal Articles

Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule

Elaine Xiang, PharmD, Hillary Prescott, PharmD, Jacob Laubach, MD, Paul Richardson, Kaitlen Reyes, NP, Irene M. Ghobrial, MD, Houry Leblebjian, PharmD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2024.
https://doi.org/10.1182/blood-2018-99-111191
Published: 2018
Journal Articles

Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)

Elias Jabbour, MD, Hagop M Kantarjian, MD, Wei Qiao, Paolo Strati, MD, Navira F Khan, Jorge E. Cortes, MD, Daniela Hoehn, MD, PhD, Jianhua Hu, Susan Obrien, MD, Jeffrey Bryan, Hillary Prescott, Courtney D. DiNardo, MD, Naval Daver, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2013) 122 (21): 2801.
https://doi.org/10.1182/blood.V122.21.2801.2801
Published: 2013
Journal Articles

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Lianchun Xiao, Al Ali Najla, Asmita Mishra, MD, Eric Padron, MD, Jeffrey E Lancet, MD, Jeffery Bryan, Hillary Prescott, David P. Steensma, MD, Mikkael A. Sekeres, MD, MS, Gail J. Roboz, MD, Alan List, MD, Hagop M Kantarjian, MD, Rami S Komrokji, MD
Journal: Blood
Blood (2013) 122 (21): 388.
https://doi.org/10.1182/blood.V122.21.388.388
Published: 2013